Healthcare Innovator “ORHub” aims to enter the Fintech industry
ORHub’s new Surgical Resource Management (“SRM”) platform, FutureOR, enables faster Case-to-Cash payments to medical device and biological suppliers.
IRVINE, CA, July 21, 2022 /OrthoSpineNews/ – ORHub, Inc. (OTC Pink: ORHB) takes shape as a medical fintech company, announcing the launch of “FutureOR”, its SRM platform, focused on enabling digital connectivity, faster provider payments and accountability for surgical implants.
The company “intends to eliminate the shortcomings hospitals and their providers face, replacing outdated documentation and legacy processes with ORHub’s unified business automation and rapid payment software,” shared Founder, CEO and CEO, CJ Wiggins. “This software can reduce the Case-to-Cash timeline (hospital to provider) by over 90%, as well as add real value to the FDA’s Unique Device Identifier (UDI) mandate for implant liability.”
“As we prepare this powerful software for release, the initial focus is on the ortho-spine surgery markets with a 12-month target of 200 hospitals,” Wiggins continues. “These facilities implant an estimated $2B+ in implanted ortho-spine devices and materials, and provide a unique opportunity for our business model. Considering the scale of the deficiencies we aim to fix with our digital solution and financial instruments, along with the tightly concentrated customer base , I am sure that ORHub will become a significant Fintech business.
————
About ORHub, Inc.
ORHub, Inc. is headquartered in Irvine, California. The company is a health innovator and fintech company with a focus on payment processes, business logistics and clinical solutions with digital and biological technologies. The company uses intelligent automation and mobile-based technologies to Change Business for Good™ and consists of four segments: Surgical Resource Management (SRM), digital payments, regenerative therapy and artificial intelligence.
ORHub’s SRM platform, “FutureOR” uses digital technologies to replace dated vendor-centric documentation and processes. The platform enables digital connectivity, faster supplier payments and implant liability for all surgically implanted medical devices and biological products. The company’s digital payments focus is on software solutions that will allow b2b suppliers of medical devices and biologics to reduce the Case-to-Cash timeline. With the acquisition of PUR Biologics, ORHub’s Regenerative Therapeutic division is focused on selling bone regenerative products, while targeting new opportunities with patented cell-based technologies. Together, these solutions form a valuable foundation for new uses of AI, quantum computing, and a mobile ecosystem for personalized patient-centered information and accessibility.
For more information, please visit: ORHub.com
###
Forward-looking statements
This release contains forward-looking statements, including the market demand for and acceptance of ORHub’s products and services, the results of the use of ORHub’s products and services, and general business conditions, particularly in the surgical, life sciences and medical device industries. Any forward-looking statements in this press release are based on ORHub’s historical performance and current plans, estimates and expectations, and are not a representation that such plans, estimates or expectations will be achieved. These forward-looking statements represent ORHub’s expectations as of the date of this press release. Subsequent events may cause these expectations to change, and ORHub disclaims any obligation to update forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional information about potential risks that could affect actual results will be included
in future filings made by ORHub and are available on the Company’s website at ORHub.com from time to time.
Consult:
Jason Brown
ORHub, Inc.
612-209-7565
